全球失眠治療產品線分析 - 2026 年（第二季洞察與臨床試驗）

隨著製藥公司、生技公司和學術研究機構加強研發治​​療慢性失眠和其他睡眠障礙的創新療法，全球失眠治療藥物研發管線正在穩步擴展。藥物研發管線的分析能夠全面揭示在臨床實驗藥物、研發階段、作用機制、給藥途徑、臨床開發進展、監管里程碑、許可活動、策略合作以及商業化機會。人們對睡眠健康的日益關注、失眠盛行率的不斷上升以及現有療法的局限性，並持續推動新藥研發的投資。目前的產業評估表明，從臨床前研究到後期臨床開發，在臨床實驗候選藥物的數量正在增加，這反映了睡眠醫學領域的持續創新。

雙重Orexin受體拮抗劑（DORA）的問世徹底改變了失眠的治療模式。 DORA透過改善入睡和維持睡眠，同時降低藥物依賴風險，革新了慢性失眠的治療。基於這項成功，研發人員正在研究下一代Orexin標靶療法、褪黑素受體促效劑、GABA受體調節劑、晝夜節律調變器以及其他新型作用機制，旨在提高睡眠品質的同時，最大限度地降低次日殘留效應和濫用風險。

神經科學、睡眠生物學、生物標記研究、藥物基因體學以及人工智慧驅動的藥物發現等領域的進步，正在加速創新治療標靶的識別。製藥公司正擴大將數位睡眠監測、穿戴式科技、電子睡眠日記和真實世界數據（REW）納入臨床開發流程，以最佳化患者篩選並更有效地評估治療效果。

研發管線也反映了藥物遞送技術的多元化，包括口服製劑、緩釋製劑以及旨在提高患者用藥便利性和依從性的新型製劑。策略性授權協議、收購和研究合作正在強化研發組合，並加速創新。隨著多種在臨床實驗藥物進入II期和III期臨床試驗階段，預計失眠治療市場的競爭格局將在預測期內加劇。

市場促進因素

失眠症盛行率上升

• 慢性失眠的發生率不斷上升，這與壓力、焦慮、老化、輪班工作和生活方式的改變有關，也持續推動人們對創新療法的需求。
• 人們越來越認知到睡眠障礙是一個重要的公共衛生問題，這推動了對藥物研發的加大投入。

基於Orexin療法的創新

• 雙重Orexin受體拮抗劑的臨床成功正在加速對下一代睡眠療法的研究，以提高療效、安全性和耐受性。
• 各公司正持續探索針對Orexin以及其他神經通路的差異化方法。

擴大醫藥投資

• 世界各地的製藥和生物技術公司持續增加對神經科學和睡眠醫學研究的投資。
• 擴大的資金籌措將用於開展更完善的臨床前研究計畫和正在進行的臨床試驗。

精準醫學的進展

• 生物標記、藥物基因體學和個人化醫療的發現，加深了我們對睡眠障礙的了解，並推動了標靶療法的開發。
• 預計這些進展將帶來更好的治療方案和更佳的長期臨床療效。

藥物研發中的技術創新

• 人工智慧、機器學習、計算生物學和數位臨床試驗技術正在提高目標人群定位、參與者招募和研究效率。
• 這些技術正在加速治療藥物的研發，同時也有助於縮短整體研發週期。

市場限制因素

高昂的藥物研發成本

• 開發治療失眠的藥物需要進行涉及大量患者的廣泛臨床評估，以及對療效和安全性的長期評估。
• 這些要求顯著增加了研發投資和商業化風險。

嚴格的監管要求

• 新型失眠療法必須證明其具有持續的臨床療效，同時最大限度地降低與依賴性、認知障礙、白天鎮靜和潛在濫用相關的風險。
• 全面的監管評估可能會延長產品開發週期。

競爭環境

• 由於現有療法和學名藥的價格競爭，在研發線產品需要有明顯的臨床差異化。
• 為了取得商業性成功，研發公司必須在療效、安全性或病患便利性方面取得有意義的改善。

目錄

第1章：引言

• 調查方法
• 調查範圍
  • 分析：按公司
  • 分析：按發展階段
  • 分析：按干預類型分類
  • 分析：按臨床試驗狀態
  • 分析：按地區
• 數據來源和檢驗
• 定義和假設

第2章 疾病概述

• 疾病分類
• 病因和風險因素
• 症狀和臨床觀察
• 診斷
• 目前治療狀況
• 流行病學和疾病負擔
• 未滿足的臨床需求

第3章執行摘要

• 臨床階段產品線概覽
• 按開發階段分類的管道分佈
• 臨床試驗活動中的主要公司
• 主要臨床實驗藥物和療法
• 各地區臨床試驗現狀
• 管道構建中的關鍵趨勢和發現

第4章：失眠動態

• 因素
• 抑制因子
• 潛在機會

第5章 管道分析/預測

• 管道分析：按公司分類
  • Eisai
  • Idorsia
  • Merck & Co.
  • Takeda Pharmaceutical Company
  • Vanda Pharmaceuticals
• 管線分析：依開發階段分類
  • 第一階段
  • 第一階段
  • 第一/二期
  • 第二階段
  • 第二/三期
  • 第三階段
• 管道分析：依干預類型分類
  • 製藥
  • 生物
  • 基因
• 產品線分析：依疾病/患者群分類
  • 慢性失眠
  • 急性/短期失眠
  • 伴隨性失眠
• 研發管線分析：依臨床試驗狀態分類
  • 我們尚未開始招募參與者。
  • 招募測試對象
  • 目前已暫停招募參與者。
  • 完成
  • 取消/撤回/暫停
• 管道分析：按地區分類
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
• 臨床試驗和病患分析
  • 按註冊患者人數統計的臨床試驗
  • 依研究設計進行的臨床試驗
  • 患者年齡要求
  • 關於患者性別的合格標準
• 贊助和合作關係分析
  • 主要商業贊助商
  • 主要學術和研究贊助商
  • 主要合作夥伴組織
  • 贊助商和合作研究者分析
• 近期和未來管道趨勢
  • 近期啟動的臨床試驗
  • 目前正在招募受試者的臨床試驗
  • 近期完成的臨床試驗
  • 後期臨床試驗即將完成
  • 近期已發表結果的臨床試驗

第6章：公司簡介

• Eisai
• Idorsia
• Merck & Co.
• Takeda Pharmaceutical Company
• Vanda Pharmaceuticals

第7章 圖表清單

第8章：圖表清單

The global insomnia drug pipeline is expanding steadily as pharmaceutical companies, biotechnology firms, and academic research organizations intensify efforts to develop innovative therapies for chronic insomnia and other sleep disorders. Drug pipeline analysis provides comprehensive insights into investigational drugs, development stages, mechanisms of action, routes of administration, clinical progress, regulatory milestones, licensing activities, strategic collaborations, and commercialization opportunities. Growing awareness of sleep health, the increasing prevalence of insomnia, and the limitations of existing therapies continue to drive investment in novel drug development. Current industry assessments indicate a growing pipeline of investigational candidates spanning preclinical research through late-stage clinical development, reflecting continued innovation in sleep medicine.

The insomnia treatment landscape has evolved significantly with the introduction of dual orexin receptor antagonists (DORAs), which have transformed the management of chronic insomnia by improving sleep onset and maintenance with a lower risk of dependence than many traditional hypnotics. Building on this success, developers are investigating next-generation orexin-targeted therapies, melatonin receptor agonists, GABA receptor modulators, circadian rhythm regulators, and other novel mechanisms designed to enhance sleep quality while minimizing next-day residual effects and abuse potential.

Advances in neuroscience, sleep biology, biomarker research, pharmacogenomics, and artificial intelligence-assisted drug discovery are accelerating the identification of innovative therapeutic targets. Drug developers are increasingly integrating digital sleep monitoring, wearable technologies, electronic sleep diaries, and real-world evidence into clinical development to improve patient selection and evaluate treatment outcomes more effectively.

The pipeline also reflects diversification in drug delivery technologies, including oral formulations, extended-release products, and novel formulations designed to improve patient convenience and adherence. Strategic licensing agreements, acquisitions, and research collaborations continue strengthening development portfolios while accelerating innovation. As several investigational therapies progress through Phase II and Phase III clinical development, the insomnia treatment landscape is expected to become increasingly competitive throughout the forecast period.

Market Drivers

Rising Prevalence of Insomnia

• The increasing incidence of chronic insomnia associated with stress, anxiety, aging populations, shift work, and lifestyle changes continues driving demand for innovative therapies.
• Growing recognition of sleep disorders as major public health concerns is supporting increased investment in drug development.

Innovation in Orexin-Based Therapies

• The clinical success of dual orexin receptor antagonists has accelerated research into next-generation sleep therapies with improved efficacy, safety, and tolerability.
• Companies continue exploring differentiated orexin-targeted approaches and additional neurological pathways.

Increasing Pharmaceutical Investment

• Global pharmaceutical and biotechnology companies continue expanding investment in neuroscience and sleep medicine research.
• Growing funding supports robust preclinical discovery programs and advanced-stage clinical trials.

Advances in Precision Medicine

• Biomarker discovery, pharmacogenomics, and personalized medicine are improving understanding of sleep disorders and enabling targeted therapeutic development.
• These advances may improve treatment selection and long-term clinical outcomes.

Technological Innovation in Drug Discovery

• Artificial intelligence, machine learning, computational biology, and digital clinical trial technologies are improving target identification, patient recruitment, and research efficiency.
• These technologies help accelerate therapeutic development while reducing overall development timelines.

Market Restraints

High Drug Development Costs

• Insomnia drug development requires extensive clinical evaluation involving large patient populations and long-term assessments of efficacy and safety.
• These requirements significantly increase research investment and commercialization risk.

Stringent Regulatory Requirements

• Novel insomnia therapies must demonstrate durable clinical benefit while minimizing risks related to dependence, cognitive impairment, daytime sedation, and abuse potential.
• Comprehensive regulatory evaluation may extend product development timelines.

Competitive Market Environment

• Established therapies and generic medications create pricing pressure and require pipeline products to demonstrate clear clinical differentiation.
• Developers must deliver meaningful improvements in efficacy, safety, or patient convenience to achieve commercial success.

Technology and Segment Insights

By Development Phase

• Phase II and Phase III candidates represent a significant portion of the active insomnia pipeline as several investigational therapies advance toward potential regulatory submission.
• Preclinical and Phase I programs continue evaluating innovative mechanisms and next-generation therapeutic approaches.

By Drug Class

• Small-molecule therapies continue to dominate the insomnia pipeline because of their established development pathways and oral administration.
• Additional innovation includes dual orexin receptor antagonists, melatonin receptor agonists, GABA receptor modulators, circadian rhythm regulators, and emerging neurological therapies.

By Mechanism of Action

• Orexin receptor antagonism remains the leading area of innovation within the insomnia pipeline.
• Additional research focuses on melatonin signaling, GABA modulation, circadian rhythm regulation, neurotransmitter balance, and novel sleep-wake regulatory pathways to improve sleep quality while reducing adverse effects.

By Route of Administration

• Oral therapies remain the preferred route of administration because of convenience and strong patient acceptance.
• Extended-release formulations and novel delivery technologies are being developed to improve treatment duration, adherence, and overall patient experience.

Regional Insights

• North America leads the global insomnia drug pipeline owing to its advanced pharmaceutical research infrastructure, strong biotechnology ecosystem, significant research investment, and extensive clinical trial capabilities. The region continues to host numerous late-stage insomnia development programs while maintaining leadership in regulatory innovation and commercialization.
• Europe remains an important center for insomnia research, supported by collaborative neuroscience programs, experienced regulatory agencies, leading academic institutions, and multinational pharmaceutical companies. Germany, the United Kingdom, France, Italy, and Spain continue contributing significantly to global pipeline development.
• Asia Pacific is expected to witness the fastest growth in insomnia drug development during the forecast period owing to increasing pharmaceutical investment, expanding biotechnology capabilities, improving clinical research infrastructure, and growing participation in multinational clinical trials across China, Japan, South Korea, India, and Australia.
• Latin America and the Middle East & Africa are gradually strengthening their participation in insomnia drug development through expanding clinical research capacity, healthcare modernization, regulatory improvements, and increased collaboration with international pharmaceutical companies.

Competitive and Strategic Outlook

• The global insomnia drug pipeline is highly competitive, with multinational pharmaceutical companies, biotechnology firms, specialty neuroscience companies, and emerging innovators actively developing differentiated therapies. Competition increasingly focuses on drugs capable of improving sleep onset, maintaining sleep throughout the night, minimizing next-day impairment, reducing dependence risk, and enhancing long-term patient outcomes.
• Organizations continue investing in next-generation orexin receptor antagonists, novel receptor modulators, small molecules, precision medicine, artificial intelligence-assisted drug discovery, biomarker research, and innovative sleep therapeutics. Strategic collaborations, licensing agreements, mergers and acquisitions, and co-development partnerships continue strengthening research capabilities while accelerating commercialization.
• Future competition is expected to emphasize personalized sleep medicine, innovative mechanisms of action, digital sleep monitoring integration, combination therapies, and treatments that address both nighttime symptoms and daytime functioning.

Conclusion

• The global insomnia drug pipeline is expected to remain active throughout the forecast period as advances in neuroscience, sleep biology, precision medicine, and digital health technologies continue transforming insomnia management. Increasing pharmaceutical investment, expanding clinical development programs, technological innovation, and supportive regulatory initiatives are expected to accelerate the introduction of safer and more effective therapies. Although high development costs, regulatory complexity, and competitive pressures remain important considerations, continued scientific progress and strategic collaboration are expected to strengthen the future insomnia treatment landscape and create significant commercial opportunities.

Key Benefits of this Report

• Insightful Analysis: Comprehensive evaluation of insomnia drug candidates, development pipelines, mechanisms of action, and innovation trends.
• Pipeline Intelligence: Understand development stage distribution, emerging technologies, and competitive positioning across the therapeutic landscape.
• Market Drivers and Future Trends: Assess scientific advances, pipeline maturity, and future commercialization opportunities.
• Actionable Recommendations: Support licensing decisions, investment planning, portfolio optimization, and research prioritization.
• Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, investors, contract research organizations, healthcare providers, consultants, and academic institutions.

What Businesses Use Our Reports For

• Drug pipeline assessment, clinical development strategy, licensing evaluation, competitive intelligence, investment analysis, partnership identification, portfolio management, commercialization planning, and regulatory strategy.

Report Coverage

• Historical analysis from 2021 to 2024, Base year 2025, and Forecast period from 2026 to 2035
• Pipeline analysis by development phase, drug class, mechanism of action, route of administration, and region
• Clinical development trends, regulatory outlook, innovation landscape, and commercialization opportunities
• Competitive landscape, strategic collaborations, licensing activities, mergers and acquisitions, and pipeline benchmarking
• Regional analysis across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Research Methodology
• 1.2. Research Scope
  • 1.2.1. Analysis by Company
  • 1.2.2. Analysis by Development Phase
  • 1.2.3. Analysis by Intervention Type
  • 1.2.4. Analysis by Clinical Trial Status
  • 1.2.5. Analysis by Geography
• 1.3. Data Sources and Validation
• 1.4. Definitions and Assumptions

2. DISEASE OVERVIEW

• 2.1. Introduction
• 2.2. Disease Classification
• 2.3. Causes and Risk Factors
• 2.4. Symptoms and Clinical Manifestations
• 2.5. Diagnosis
• 2.6. Current Treatment Landscape
• 2.7. Epidemiology and Disease Burden
• 2.8. Unmet Clinical Needs

3. EXECUTIVE SUMMARY

• 3.1. Clinical-Stage Pipeline Overview
• 3.2. Pipeline Distribution by Development Phase
• 3.3. Leading Companies by Clinical Trial Activity
• 3.4. Leading Investigational Drugs and Interventions
• 3.5. Geographic Clinical Trial Landscape
• 3.6. Key Pipeline Trends and Findings

4. INSOMNIA PIPELINE DYNAMICS

• 4.1. Drivers
• 4.2. Restraints
• 4.3. Pipeline Opportunities

5. PIPELINE ANALYSIS / OUTLOOK

• 5.1. PIPELINE ANALYSIS BY COMPANY
  • 5.1.1. Eisai
  • 5.1.2. Idorsia
  • 5.1.3. Merck & Co.
  • 5.1.4. Takeda Pharmaceutical Company
  • 5.1.5. Vanda Pharmaceuticals
• 5.2. PIPELINE ANALYSIS BY DEVELOPMENT PHASE
  • 5.2.1. Early Phase I
  • 5.2.2. Phase I
  • 5.2.3. Phase I/II
  • 5.2.4. Phase II
  • 5.2.5. Phase II/III
  • 5.2.6. Phase III
• 5.3. PIPELINE ANALYSIS BY INTERVENTION TYPE
  • 5.3.1. Drug
  • 5.3.2. Biological
  • 5.3.3. Genetic
• 5.4. PIPELINE ANALYSIS BY DISEASE / PATIENT SEGMENT
  • 5.4.1. Chronic Insomnia
  • 5.4.2. Acute / Short-Term Insomnia
  • 5.4.3. Comorbid Insomnia
• 5.5. PIPELINE ANALYSIS BY CLINICAL TRIAL STATUS
  • 5.5.1. Not Yet Recruiting
  • 5.5.2. Recruiting
  • 5.5.3. Active, Not Recruiting
  • 5.5.4. Completed
  • 5.5.5. Terminated / Withdrawn / Suspended
• 5.6. PIPELINE ANALYSIS BY GEOGRAPHY
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia-Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa
• 5.7. CLINICAL TRIAL AND PATIENT ANALYSIS
  • 5.7.1. Clinical Trials by Patient Enrollment
  • 5.7.2. Clinical Trials by Study Design
  • 5.7.3. Patient Age Eligibility
  • 5.7.4. Patient Sex Eligibility
• 5.8. SPONSOR AND COLLABORATION ANALYSIS
  • 5.8.1. Leading Commercial Sponsors
  • 5.8.2. Leading Academic and Research Sponsors
  • 5.8.3. Leading Collaborating Organizations
  • 5.8.4. Sponsor-Collaborator Analysis
• 5.9. RECENT AND UPCOMING PIPELINE ACTIVITY
  • 5.9.1. Recently Initiated Clinical Trials
  • 5.9.2. Newly Recruiting Clinical Trials
  • 5.9.3. Recently Completed Clinical Trials
  • 5.9.4. Late-Stage Trials Approaching Primary Completion
  • 5.9.5. Trials with Recently Posted Results

6. COMPANY PROFILES

• 6.1. Eisai
• 6.2. Idorsia
• 6.3. Merck & Co.
• 6.4. Takeda Pharmaceutical Company
• 6.5. Vanda Pharmaceuticals

7. LIST OF TABLES

8. LIST OF FIGURES